Paolo Marchetti | Ricerc@Sapienza

Pubblicazioni

Titolo	Pubblicato in	Anno
DNA damage response and repair (DDR) gene mutations as an alternative mechanism to generate high TMB in never smoker NSCLC patients	ANNALS OF ONCOLOGY	2022
EP07.01-021 Clinical and Biochemical Profiling of Pleural Mesothelioma Patients Treated With Immunotherapy	JOURNAL OF THORACIC ONCOLOGY	2022
New driver alterations in non-small cell lung cancer: A narrative review	PRECISION CANCER MEDICINE	2022
Systemic effect of radiotherapy before or after nivolumab in lung cancer: an observational, retrospective, multicenter study	TUMORI	2022
A regional survey on Merkel cell carcinoma: a plea for uniform patient journey modeling and diagnostic–therapeutic pathway	CURRENT ONCOLOGY	2022
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index	EUROPEAN JOURNAL OF CANCER	2021
Palliative- and non-palliative indications for glucocorticoids use in course of immune-checkpoint inhibition. Current evidence and future perspectives	CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY	2021
Cdk4/6 inhibitor treatments in patients with hormone receptor positive, her2 negative advanced breast cancer: Potential molecular mechanisms, clinical implications and future perspectives	CANCERS	2021
Drug–drug interactions and pharmacogenomic evaluation in colorectal cancer patients: The new drug-pin® system comprehensive approach	PHARMACEUTICALS	2021
The role of opioids in cancer response to immunotherapy	JOURNAL OF TRANSLATIONAL MEDICINE	2021
Standard of care and promising new agents for the treatment of mesenchymal triple-negative breast cancer	CANCERS	2021
CT based radiomic approach on first line pembrolizumab in lung cancer	SCIENTIFIC REPORTS	2021
New immunological potential markers for triple negative breast cancer: IL18R1, CD53, TRIM, Jaw1, LTB, PTPRCAP	DISCOVER ONCOLOGY	2021
Evaluation of drug-drug interactions in EGFR-mutated non-small-cell lung cancer patients during treatment with tyrosine-kinase inhibitors	JOURNAL OF PERSONALIZED MEDICINE	2021
H-Ras gene takes part to the host immune response to COVID-19	CELL DEATH DISCOVERY	2021
Weekly chemotherapy as first line treatment in frail head and neck cancer patients in the immunotherapy era	JOURNAL OF TRANSLATIONAL MEDICINE	2021
Immune checkpoint inhibitors and pre-existing antinuclear antibodies: the rheumatologist point of view	CLINICAL & TRANSLATIONAL ONCOLOGY	2021
A Case of Pathological Complete Response and Resolution of Dermatomyositis Following Neoadjuvant Chemotherapy in HER2-Positive Early Breast Cancer	CURRENT ONCOLOGY	2021
The role of soluble LAG3 and soluble immune checkpoints profile in advanced head and neck cancer: a pilot study	JOURNAL OF PERSONALIZED MEDICINE	2021
Increased kynurenine-to-tryptophan ratio in the serum of patients infected with SARS-CoV2: An observational cohort study	BIOCHIMICA ET BIOPHYSICA ACTA. MOLECULAR BASIS OF DISEASE	2021